KBI Biopharma Unveils KBI PUREplatform™, a Game-Changing Microbial Expression Offering to Redefine Biopharmaceutical ...
Platform leverages proprietary PUREcoli™ strain and cutting-edge screening packages for unmatched efficiencies and optimized production processes
JSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as one Organiz...
KBI’s new model will enhance operational efficiencies, drive strategic clarity, and accelerate innovation for global biopharma customers
KBI Biopharma Appoints Marykay Marchigiani as Chief Financial Officer and Sigma Mostafa, Ph.D., as Chief Scientific O...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the appointment of Marykay Marchigiani as Chief Financial Officer and Sigma Mostafa, Ph.D., as Chief Scientific Officer. The ...
KBI Biopharma Appoints David Stewart as Site Head of Durham Mammalian cGMP Manufacturing Facility
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the appointment of David Stewart as the new SVP and Site Head of KBI’s mammalian cGMP manufacturing facility in Durham, North...
KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO
KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies, today announced the appointment of J.D. Mowery as Chief Executive Officer (CEO).
Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed Gmb...
JSR Begins Development of Raw Materials from Biomass
Through joint development with Bacchus Bio innovation, JSR will develop and produce raw materials for its key biomass products utilizing synthetic biology.
KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility Five Months After O...
Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully
Crown Bioscience opens Singapore Laboratory and Establishes Local Commercial Partner
The new facility expands the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.
Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs Targeting Cancer and Autoimmune Diseases
Under the initial agreement, Similis will be responsible for cell line development, analytics, process development, and cGMP production, leading to pharmacokinetics/pharmacodynamic clinical trials